BackAryx Therapeutics Overview

Aryx Therapeutics Net Income

Latest net income for ARYX: $-18M, below the Healthcare sector average of $16B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$2.51M
↑ 69.15% YoY

As of Sep 2010

Annual Net Income (TTM)

-$18.33M
↑ 54.67% YoY

Trailing 12 months ending Sep 2010

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Aryx Therapeutics (ARYX) FAQ

Aryx Therapeutics (ARYX) currently reports a net income of $-18M as of September 2010. That compares with $-40M in the prior-year period — up 54.7% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Aryx Therapeutics's net income history and peer comparisons.

Aryx Therapeutics's net income increased from $-40M to $-18M — a 54.7% year-over-year increase (period ending September 2010). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aryx Therapeutics's net income of $-18M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aryx Therapeutics reported $-18M in net income as of September 2010. That compares with $-40M in the prior-year period — up 54.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-18M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Aryx Therapeutics, and consider following ARYX for alerts when major investors trade the stock.